Novel perspectives in the management of decompensated cirrhosis
- 19 July 2018
- journal article
- review article
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 15 (12) , 753-764
Abstract
The current approaches to the management of patients with decompensated cirrhosis are based on targeted strategies aimed at preventing or treating specific complications of the disease. The improved knowledge of the pathophysiological background of advanced cirrhosis, represented by a sustained systemic inflammation strictly linked to a circulatory dysfunction, provides a novel paradigm for the management of these patients, with the ambitious target of modifying the course of the disease by preventing the onset of complications and multiorgan failure; these interventions will eventually improve patients’ quality of life, prolong survival and reduce health-care costs. Besides aetiological treatments, these goals could be achieved by persistently antagonizing key pathophysiological events, such as portal hypertension, abnormal bacterial translocation from the gut, liver damage, systemic inflammation, circulatory dysfunction and altered immunological responses. Interestingly, in addition to strategies based on new therapeutic agents, these targets can be tackled by employing drugs that are already used in patients with cirrhosis for different indications or in other clinical settings, including non-absorbable oral antibiotics, non-selective β-blockers, human albumin and statins. The scope of the present Review includes reporting updated information on the treatments that promise to influence the course of advanced cirrhosis and thus act as disease-modifying agents.Keywords
This publication has 133 references indexed in Scilit:
- Targeting the Gut–Liver Axis in Cirrhosis: Antibiotics and Non-Selective β-BlockersAdvances in Therapy, 2013
- Long‐term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosisJournal of Gastroenterology and Hepatology, 2013
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- Muscle Wasting Is Associated With Mortality in Patients With CirrhosisClinical Gastroenterology and Hepatology, 2012
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptorsNature Immunology, 2010
- Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization ProfilesAntimicrobial Agents and Chemotherapy, 2010
- Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthaseHepatology, 2007
- The role of the sympathetic nervous system in intestinal inflammationGut, 2006
- A Randomized Unblinded Pilot Study Comparing Albumin Versus Hydroxyethyl Starch in Spontaneous Bacterial Peritonitis * #Hepatology, 2005
- Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangementHepatology, 2003